Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics appoints ex- Skyepharma man as FD

Peter Jensen, Allergy’s chairman said Wykeham’s experience in life sciences was well suited to Allergy.
Picture of handshake
New Allergy FD is experienced life sciences specialist

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has appointed Nick Wykeham as its new finance director.

Wykeham, 51, was group financial controller at Skypharma until August last year, with a stint at ICI business Quest prior to that.

Peter Jensen, Allergy’s chairman said Wykeham’s experience in life sciences was well suited to Allergy.  

He replaces Ian Postlethwaite who resigned in March after 14 years with the company and taken up the post of chief financial officer at healthcare company investor NetScientific (LON:NSCI).

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

picture of doctors
July 11 2017
The focus has switched to new, higher value “finished device products”,
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use